Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LENZ Therapeutics (LENZ) Retained Earnings (2022 - 2025)

LENZ Therapeutics (LENZ) has disclosed Retained Earnings for 4 consecutive years, with $242000.0 as the latest value for Q4 2025.

  • Quarterly Retained Earnings rose 100.17% to $242000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $242000.0 through Dec 2025, up 100.17% year-over-year, with the annual reading at $242000.0 for FY2025, 100.17% up from the prior year.
  • Retained Earnings for Q4 2025 was $242000.0 at LENZ Therapeutics, up from $227000.0 in the prior quarter.
  • The five-year high for Retained Earnings was $523000.0 in Q3 2024, with the low at -$344.1 million in Q3 2023.
  • Average Retained Earnings over 4 years is -$114.5 million, with a median of -$122.1 million recorded in 2024.
  • The sharpest move saw Retained Earnings plummeted 44972.69% in 2024, then soared 100.17% in 2025.
  • Over 4 years, Retained Earnings stood at -$242.4 million in 2022, then tumbled by 41.95% to -$344.1 million in 2023, then soared by 57.86% to -$145.0 million in 2024, then skyrocketed by 100.17% to $242000.0 in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at $242000.0, $227000.0, and -$174.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.